View Cart (0 items)
Processing e-News / Global Processing e-News / Pharmaceutical / Pharmaceutical / North America

Mexico's Neolpharma opens R&D facility in Puerto Rico

February 05, 2014
/ Print / Reprints /
| Share More
/ Text Size+

<photocredit>RGtimeline/iStockphoto/Thinkstock</photocredit>

The first center for research and development of generic pharmaceutical products in Puerto Rico has been officially launched. The inauguration ceremony was led by Puerto Rican Gov. Alejandro Garcia Padilla, who stated that the new facility was a major milestone for the Caribbean island on its way to economic diversification and job creation.

The Center for the Development and Innovation of Pharmaceutical Products, or Cediprof, will focus on research and experimentation of generic drugs. It was built thanks to a $12 million investment by Mexican company Neolpharma, which established its presence in Puerto Rico in 2013, reports said.

RELATED: Global spending on medicines to grow by up to 6% per year through 2017

The project includes a 2,000-square-foot pilot plant that will test new pharmaceutical products, as well as an analytic and forensic laboratory and a 4,000-square-foot storage facility. The center is equipped with state-of-the-art technology to produce a wide range of pharmaceutical goods, including liquid and solid forms, tablets, capsules and beads, Neolpharma said. The maximum capacity of the facility is 5.2 billion units annually.

By 2015 the research and development center is expected to work on between 12 and 15 new pharmaceutical products that will then be submitted to the U.S. Food and Drug Administration for approval. If they are granted approval from the regulator, Neolpharma will start manufacturing them commercially for the U.S. market.

You must login or register in order to post a comment.